Starpharma Holdings Ltd
PQ6
Company Profile
Business description
Starpharma Holdings Ltd is an Australia-based company engaged in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications. It focuses on the development of VivaGel for the management and prevention of bacterial vaginosis and as a condom coating, and VIRALEZE, an antiviral nasal spray.
Contact
4-6 Southampton Crescent
Abbotsford
MelbourneVIC3067
AUST: +61 385322700
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2027
Employees
32
Stocks News & Analysis
stocks
Global tensions drive profitability for ASX energy provider
Supply disruptions turbocharge refining profits and lift earnings forecasts for ASX energy share.
stocks
ASX energy share undervalued ahead of earnings
Pricing strength outweighs temporary production headwinds.
stocks
Tesla: Reported China divestiture plan could clear path for SpaceX merger
Media report says Tesla is exploring divestiture plans to ease regulatory approval of a Tesla-SpaceX merger.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,275.00 | 88.90 | 0.97% |
| CAC 40 | 8,613.82 | 104.18 | 1.22% |
| DAX 40 | 26,001.31 | 372.07 | 1.45% |
| Dow JONES (US) | 53,178.41 | 693.38 | 1.32% |
| FTSE 100 | 10,857.70 | 10.35 | -0.10% |
| HKSE | 25,990.12 | 19.28 | -0.07% |
| NASDAQ | 25,913.90 | 540.04 | 2.13% |
| Nikkei 225 | 63,083.97 | 670.93 | -1.05% |
| NZX 50 Index | 13,858.59 | 83.66 | 0.61% |
| S&P 500 | 7,600.50 | 110.78 | 1.48% |
| S&P/ASX 200 | 9,112.90 | 89.90 | 1.00% |
| SSE Composite Index | 3,810.46 | 0.80 | 0.02% |